Decoding moxifloxacin resistance in pre-XDR tuberculosis using MGIT 960 and MYCOTB AST
- 15 June 2026
- journal article
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 62, 101174
Abstract
No abstract availableKeywords
Funding Information
- All-India Institute of Medical Sciences
This publication has 22 references indexed in Scilit:
- Development of inhaled moxifloxacin-metformin formulation as an alternative for pulmonary tuberculosis treatmentInternational Journal of Pharmaceutics, 2024
- Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnosticsTuberculosis, 2023
- Clinical Relevance of Rifampicin‐Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2022
- Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant TuberculosisOpen Forum Infectious Diseases, 2021
- Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in AdultsMedicine, 2020
- Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strainsEuropean Journal of Medicinal Chemistry, 2019
- Association of gyrA and rrs gene mutations detected by MTBDRsl V1 on Mycobacterium tuberculosis strains of diverse genetic background from IndiaScientific Reports, 2018
- A Review of Moxifloxacin for the Treatment of Drug‐Susceptible TuberculosisThe Journal of Clinical Pharmacology, 2017
- Sensititre MycoTB Plate Compared to Bactec MGIT 960 for First- and Second-Line Antituberculosis Drug Susceptibility Testing in Tanzania: a Call To Operationalize MICsAntimicrobial Agents and Chemotherapy, 2015
- Sensititre MYCOTB MIC Plate for Testing Mycobacterium tuberculosis Susceptibility to First- and Second-Line DrugsAntimicrobial Agents and Chemotherapy, 2014